|
|
|
|
|
News and Articles on Immunotoxin
JCI table of contents: November 23 2005 Nov 24, 2005
In their study appearing online on November 23 in advance of print publication in the December issue of the Journal of Clinical Investigation, Johannes Vieweg and colleagues show that the immunotoxin DAB389IL-2 selectively eliminates CD25-expressing regulatory T cells in cancer patients, without any toxic effects. This strategy significantly improved the stimulation of tumor-specific T cell responses in these cancer patients, compared to vaccination alone. (EurekAlert!)
Cambridge Antibody Technology Acquires Oncology Product Candidates from Genencor Nov 1, 2005
The candidates are both immunotoxins comprising an antibody fragment that targets the CD22 receptor on B-lymphocytes fused to a toxin molecule ... GCR-3888 is an immunotoxin fusion protein between a murine anti-CD22 disulphide-linked Fv antibody fragment (dsFv) and the Pseudomonas exotoxin PE38, and GCR-8015 is an optimized version of GCR-3888 with increased affinity for CD22 ... The anti-CD22 immunotoxins GCR-3888 and GCR-8015 comprise a dsFv that targets the CD22 receptor, fused with a... (PR Newswire)
CAT buys part of Genencor's Health Care ops from Danisco for 14 mln usd UPDATE Nov 1, 2005
GCR-3888 has demonstrated the potential opportunity from utilising this immunotoxin approach in HCL and we look forward to exploring the mechanism in a wider range of B-cell malignancies, including NHL and CLL, and to working in collaboration with the NCI.. CAT added it has hired ten key former staff of Genencor who will continue to be responsible for the development of these programmes, and has thereby established a CAT operation in the US for the first time. (Forbes)
[ Terms Of Use | Privacy | About ]
©1998-2007 SurfWax, Inc.
All rights reserved. Patents pending.
|
|
|
Copyright SurfWax, Inc. 2007
|
|
